Halaven Use In Pregnancy & Lactation

Women of childbearing age must be advised to avoid becoming pregnant whilst they or their male partner are receiving HALAVEN and should use effective contraception during and up to 3 months after treatment.
Pregnancy: There is no information on the use of HALAVEN in pregnant women. Eribulin is embryotoxic, foetotoxic, and teratogenic in rats, and testicular toxicity has been revealed in rats and dogs (see Pharmacology: Toxicology: Preclinical safety data under Actions). HALAVEN should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.
Breastfeeding: There is insufficient information on the excretion of eribulin or its metabolites in human or animal breast milk. A risk to newborn or infants cannot be excluded and therefore HALAVEN should not be used during breast feeding (see Contraindications).
Fertility: Male patients should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with HALAVEN.